Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Molecular mechanisms of pore formation and membrane disruption by the antimicrobial lantibiotic peptide Mutacin 1140.

Pokhrel R, Bhattarai N, Baral P, Gerstman BS, Park JH, Handfield M, Chapagain PP.

Phys Chem Chem Phys. 2019 Jun 21;21(23):12530-12539. doi: 10.1039/c9cp01558b. Epub 2019 May 31.

PMID:
31147666
2.

Preclinical evaluation of the maximum tolerated dose and toxicokinetics of enteric-coated lantibiotic OG253 capsules.

Rajeshkumar NV, Kers JA, Moncrief S, Defusco AW, Park JH, Handfield M.

Toxicol Appl Pharmacol. 2019 Jul 1;374:32-40. doi: 10.1016/j.taap.2019.04.019. Epub 2019 Apr 26.

PMID:
31034929
3.

Pharmacological, Toxicological, and Dose Range Assessment of OG716, a Novel Lantibiotic for the Treatment of Clostridium difficile-Associated Infection.

Pulse ME, Weiss WJ, Kers JA, DeFusco AW, Park JH, Handfield M.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e01904-18. doi: 10.1128/AAC.01904-18. Print 2019 Apr.

PMID:
30670434
4.

Blueprints for the rational design of therapeutic mutacin 1140 variants.

Kers JA, Sharp RE, Muley S, Mayo M, Colbeck J, Zhu Y, DeFusco AW, Park JH, Handfield M.

Chem Biol Drug Des. 2018 Dec;92(6):1940-1953. doi: 10.1111/cbdd.13365. Epub 2018 Aug 18.

PMID:
30010233
5.

OG716: Designing a fit-for-purpose lantibiotic for the treatment of Clostridium difficile infections.

Kers JA, DeFusco AW, Park JH, Xu J, Pulse ME, Weiss WJ, Handfield M.

PLoS One. 2018 Jun 12;13(6):e0197467. doi: 10.1371/journal.pone.0197467. eCollection 2018.

6.

Mutacin 1140 Lantibiotic Variants Are Efficacious Against Clostridium difficile Infection.

Kers JA, Sharp RE, Defusco AW, Park JH, Xu J, Pulse ME, Weiss WJ, Handfield M.

Front Microbiol. 2018 Mar 16;9:415. doi: 10.3389/fmicb.2018.00415. eCollection 2018.

7.

Identification of genes expressed in cultures of E. coli lysogens carrying the Shiga toxin-encoding prophage Φ24B.

Riley LM, Veses-Garcia M, Hillman JD, Handfield M, McCarthy AJ, Allison HE.

BMC Microbiol. 2012 Mar 22;12:42. doi: 10.1186/1471-2180-12-42.

8.

Identification of Leishmania proteins preferentially released in infected cells using change mediated antigen technology (CMAT).

Kima PE, Bonilla JA, Cho E, Ndjamen B, Canton J, Leal N, Handfield M.

PLoS Negl Trop Dis. 2010 Oct 5;4(10). pii: e842. doi: 10.1371/journal.pntd.0000842.

9.

Use of in vivo-induced antigen technology (IVIAT) to identify virulence factors of Porphyromonas gingivalis.

Wallet SM, Chung J, Handfield M.

Methods Mol Biol. 2010;666:181-95. doi: 10.1007/978-1-60761-820-1_13.

PMID:
20717786
10.

Role of the ATM-checkpoint kinase 2 pathway in CDT-mediated apoptosis of gingival epithelial cells.

Alaoui-El-Azher M, Mans JJ, Baker HV, Chen C, Progulske-Fox A, Lamont RJ, Handfield M.

PLoS One. 2010 Jul 23;5(7):e11714. doi: 10.1371/journal.pone.0011714.

11.

Porphyromonas gingivalis infection-induced tissue and bone transcriptional profiles.

Meka A, Bakthavatchalu V, Sathishkumar S, Lopez MC, Verma RK, Wallet SM, Bhattacharyya I, Boyce BF, Handfield M, Lamont RJ, Baker HV, Ebersole JL, Kesavalu L.

Mol Oral Microbiol. 2010 Feb;25(1):61-74. doi: 10.1111/j.2041-1014.2009.00555.x.

12.

Subgingival bacterial colonization profiles correlate with gingival tissue gene expression.

Papapanou PN, Behle JH, Kebschull M, Celenti R, Wolf DL, Handfield M, Pavlidis P, Demmer RT.

BMC Microbiol. 2009 Oct 18;9:221. doi: 10.1186/1471-2180-9-221.

13.

The degree of microbiome complexity influences the epithelial response to infection.

Mans JJ, von Lackum K, Dorsey C, Willis S, Wallet SM, Baker HV, Lamont RJ, Handfield M.

BMC Genomics. 2009 Aug 18;10:380. doi: 10.1186/1471-2164-10-380.

14.

Biomarkers for infants at risk for necrotizing enterocolitis: clues to prevention?

Young C, Sharma R, Handfield M, Mai V, Neu J.

Pediatr Res. 2009 May;65(5 Pt 2):91R-97R. doi: 10.1203/PDR.0b013e31819dba7d. Review.

15.

Transcriptomes in healthy and diseased gingival tissues.

Demmer RT, Behle JH, Wolf DL, Handfield M, Kebschull M, Celenti R, Pavlidis P, Papapanou PN.

J Periodontol. 2008 Nov;79(11):2112-24. doi: 10.1902/jop.2008.080139 .

16.

Role of Porphyromonas gingivalis SerB in gingival epithelial cell cytoskeletal remodeling and cytokine production.

Hasegawa Y, Tribble GD, Baker HV, Mans JJ, Handfield M, Lamont RJ.

Infect Immun. 2008 Jun;76(6):2420-7. doi: 10.1128/IAI.00156-08. Epub 2008 Apr 7.

17.

Application of in vivo induced antigen technology (IVIAT) to Bacillus anthracis.

Rollins SM, Peppercorn A, Young JS, Drysdale M, Baresch A, Bikowski MV, Ashford DA, Quinn CP, Handfield M, Hillman JD, Lyons CR, Koehler TM, Calderwood SB, Ryan ET.

PLoS One. 2008 Mar 19;3(3):e1824. doi: 10.1371/journal.pone.0001824.

18.
19.

Identification of Tannerella forsythia antigens specifically expressed in patients with periodontal disease.

Yoo JY, Kim HC, Zhu W, Kim SM, Sabet M, Handfield M, Hillman J, Progulske-Fox A, Lee SW.

FEMS Microbiol Lett. 2007 Oct;275(2):344-52. Epub 2007 Sep 14.

20.

Intrinsic apoptotic pathways of gingival epithelial cells modulated by Porphyromonas gingivalis.

Mao S, Park Y, Hasegawa Y, Tribble GD, James CE, Handfield M, Stavropoulos MF, Yilmaz O, Lamont RJ.

Cell Microbiol. 2007 Aug;9(8):1997-2007. Epub 2007 Apr 5.

21.

Gingival epithelial cell transcriptional responses to commensal and opportunistic oral microbial species.

Hasegawa Y, Mans JJ, Mao S, Lopez MC, Baker HV, Handfield M, Lamont RJ.

Infect Immun. 2007 May;75(5):2540-7. Epub 2007 Feb 16.

22.

Identification of in vivo-induced bacterial protein antigens during human infection with Salmonella enterica serovar Typhi.

Harris JB, Baresch-Bernal A, Rollins SM, Alam A, LaRocque RC, Bikowski M, Peppercorn AF, Handfield M, Hillman JD, Qadri F, Calderwood SB, Hohmann E, Breiman RF, Brooks WA, Ryan ET.

Infect Immun. 2006 Sep;74(9):5161-8.

23.

In vivo induced antigen technology (IVIAT) and change mediated antigen technology (CMAT).

Handfield M, Hillman JD.

Infect Disord Drug Targets. 2006 Sep;6(3):327-34. Review.

PMID:
16918490
24.

Microarray analysis of human epithelial cell responses to bacterial interaction.

Mans JJ, Lamont RJ, Handfield M.

Infect Disord Drug Targets. 2006 Sep;6(3):299-309. Review.

PMID:
16918488
25.

Distinctive characteristics of transcriptional profiles from two epithelial cell lines upon interaction with Actinobacillus actinomycetemcomitans.

Mans JJ, Baker HV, Oda D, Lamont RJ, Handfield M.

Oral Microbiol Immunol. 2006 Aug;21(4):261-7.

PMID:
16842512
26.

Identification of group A Streptococcus antigenic determinants upregulated in vivo.

Salim KY, Cvitkovitch DG, Chang P, Bast DJ, Handfield M, Hillman JD, de Azavedo JC.

Infect Immun. 2005 Sep;73(9):6026-38.

27.

Genes of periodontopathogens expressed during human disease.

Song YH, Kozarov EV, Walters SM, Cao SL, Handfield M, Hillman JD, Progulske-Fox A.

Ann Periodontol. 2002 Dec;7(1):38-42.

PMID:
16013215
28.

Distinct transcriptional profiles characterize oral epithelium-microbiota interactions.

Handfield M, Mans JJ, Zheng G, Lopez MC, Mao S, Progulske-Fox A, Narasimhan G, Baker HV, Lamont RJ.

Cell Microbiol. 2005 Jun;7(6):811-23.

PMID:
15888084
29.

In vivo induced genes in human diseases.

Handfield M, Progulske-Fox A, Hillman JD.

Periodontol 2000. 2005;38:123-34. No abstract available.

PMID:
15853939
30.

Use of in vivo-induced antigen technology for identification of Escherichia coli O157:H7 proteins expressed during human infection.

John M, Kudva IT, Griffin RW, Dodson AW, McManus B, Krastins B, Sarracino D, Progulske-Fox A, Hillman JD, Handfield M, Tarr PI, Calderwood SB.

Infect Immun. 2005 May;73(5):2665-79.

31.
32.

In vivo induced antigen technology (IVIAT).

Rollins SM, Peppercorn A, Hang L, Hillman JD, Calderwood SB, Handfield M, Ryan ET.

Cell Microbiol. 2005 Jan;7(1):1-9. Review.

PMID:
15617518
33.

In vivo induced antigenic determinants of Actinobacillus actinomycetemcomitans.

Cao SL, Progulske-Fox A, Hillman JD, Handfield M.

FEMS Microbiol Lett. 2004 Aug 1;237(1):97-103.

34.
35.

Characterization and pathogenic significance of Vibrio vulnificus antigens preferentially expressed in septicemic patients.

Kim YR, Lee SE, Kim CM, Kim SY, Shin EK, Shin DH, Chung SS, Choy HE, Progulske-Fox A, Hillman JD, Handfield M, Rhee JH.

Infect Immun. 2003 Oct;71(10):5461-71.

36.

Use of in vivo-induced antigen technology (IVIAT) to identify genes uniquely expressed during human infection with Vibrio cholerae.

Hang L, John M, Asaduzzaman M, Bridges EA, Vanderspurt C, Kirn TJ, Taylor RK, Hillman JD, Progulske-Fox A, Handfield M, Ryan ET, Calderwood SB.

Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8508-13. Epub 2003 Jun 25.

37.

Identification of Candida albicans genes induced during thrush offers insight into pathogenesis.

Cheng S, Clancy CJ, Checkley MA, Handfield M, Hillman JD, Progulske-Fox A, Lewin AS, Fidel PL, Nguyen MH.

Mol Microbiol. 2003 Jun;48(5):1275-88.

38.

In vivo expression of bacterial genes during human infections.

Handfield M, Seifert T, Hillman JD.

Methods Mol Med. 2003;71:225-42. Review. No abstract available.

PMID:
12374023
39.

IVIAT: a novel method to identify microbial genes expressed specifically during human infections.

Handfield M, Brady LJ, Progulske-Fox A, Hillman JD.

Trends Microbiol. 2000 Jul;8(7):336-9. Review.

PMID:
10878769
40.

In vivo-induced genes in Pseudomonas aeruginosa.

Handfield M, Lehoux DE, Sanschagrin F, Mahan MJ, Woods DE, Levesque RC.

Infect Immun. 2000 Apr;68(4):2359-62.

41.

Strategies for isolation of in vivo expressed genes from bacteria.

Handfield M, Levesque RC.

FEMS Microbiol Rev. 1999 Jan;23(1):69-91. Review.

42.

ASD-GFP vectors for in vivo expression technology in Pseudomonas aeruginosa and other gram-negative bacteria.

Handfield M, Schweizer HP, Mahan MJ, Sanschagrin F, Hoang T, Levesque RC.

Biotechniques. 1998 Feb;24(2):261-4.

43.

Differential media for quantitative recovery of waterborne Aeromonas hydrophila.

Handfield M, Simard P, Letarte R.

Appl Environ Microbiol. 1996 Sep;62(9):3544-7.

44.

Supplemental Content

Loading ...
Support Center